Cumulative incidence of inhibitors in patients treated with either plasma-derived or recombinant products in the 3 studies that reported a direct comparison of products
| Study . | Plasma-derived products (%) . | Recombinant products (%) . |
|---|---|---|
| Goudemand et al1 | 27/86 (31) | 7/62 (11) |
| Chalmers et al2 | 47/172 (27) | 18/132 (14) |
| CANAL study3 | 53/181 (29) | 29/135 (21) |
| Study . | Plasma-derived products (%) . | Recombinant products (%) . |
|---|---|---|
| Goudemand et al1 | 27/86 (31) | 7/62 (11) |
| Chalmers et al2 | 47/172 (27) | 18/132 (14) |
| CANAL study3 | 53/181 (29) | 29/135 (21) |
Patients are categorized according to the products of their first exposure to factor VIII.